Sulfonylureas and Daily Blood Glucose Profiles in Elderly Diabetics
The aim of this study is to clarify the relationship between the efficacy of sulfonylureas and duration of diabetes in elderly diabetics. Daily blood glucose profiles were measured in 87 Type 2 elderly diabetic patients on sulfonylureas (tolbutamide, gliclazide or glibenclamide). Plasma glucose conc...
Saved in:
| Published in | Nihon Rōnen Igakkai zasshi Vol. 36; no. 10; pp. 715 - 720 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
Japan
The Japan Geriatrics Society
1999
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0300-9173 |
| DOI | 10.3143/geriatrics.36.715 |
Cover
| Abstract | The aim of this study is to clarify the relationship between the efficacy of sulfonylureas and duration of diabetes in elderly diabetics. Daily blood glucose profiles were measured in 87 Type 2 elderly diabetic patients on sulfonylureas (tolbutamide, gliclazide or glibenclamide). Plasma glucose concentrations were determined at 08.00 (before breakfast), 10.00, 12.00 (before lunch), 14.00, 18.00 (before dinner), 20.00, 24.00, 03.00, 06.00, 08.00 hours. The subjects were divided into 4 subgroups, according to their duration of the diabetes (<10, 10-14, 15-19, 20 or more years). Mean plasma glucose values at 08.00, 10.00, 20.00, 03.00 and 06.00 hours were not significantly different among the four groups. However, mean plasma glucose values at 12.00, 14.00, 18.00, 00.00 hours and mean total blood glucose area under the daily profile (total BG) were significantly different among the four groups and the values in patients with a history of diabetes of 15 years or more increased. Duration of diabetes positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00, 03.00 hours and total BG, and the dose of sulfonylureas positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00 hours and total BG in multiple regression analysis. These results suggest that duration of diabetes and dose of sulfonylureas are important determinants of blood glucose control with sulfonylureas in elderly diabetic patients. |
|---|---|
| AbstractList | The aim of this study is to clarify the relationship between the efficacy of sulfonylureas and duration of diabetes in elderly diabetics. Daily blood glucose profiles were measured in 87 Type 2 elderly diabetic patients on sulfonylureas (tolbutamide, gliclazide or glibenclamide). Plasma glucose concentrations were determined at 08.00 (before breakfast), 10.00, 12.00 (before lunch), 14.00, 18.00 (before dinner), 20.00, 24.00, 03.00, 06.00, 08.00 hours. The subjects were divided into 4 sub-groups, according to their duration of the diabetes (< 10, 10-14, 15-19, 20 or more years). Mean plasma glucose values at 08.00, 10.00, 20.00, 03.00 and 06.00 hours were not significantly different among the four groups. However, mean plasma glucose values at 12.00, 14.00, 18.00, 00.00 hours and mean total blood glucose area under the daily profile (total BG) were significantly different among the four groups and the values in patients with a history of diabetes of 15 years or more increased. Duration of diabetes positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00, 03.00 hours and total BG, and the dose of sulfonylureas positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00 hours and total BG in multiple regression analysis. These results suggest that duration of diabetes and dose of sulfonylureas are important determinants of blood glucose control with sulfonylureas in elderly diabetic patients.The aim of this study is to clarify the relationship between the efficacy of sulfonylureas and duration of diabetes in elderly diabetics. Daily blood glucose profiles were measured in 87 Type 2 elderly diabetic patients on sulfonylureas (tolbutamide, gliclazide or glibenclamide). Plasma glucose concentrations were determined at 08.00 (before breakfast), 10.00, 12.00 (before lunch), 14.00, 18.00 (before dinner), 20.00, 24.00, 03.00, 06.00, 08.00 hours. The subjects were divided into 4 sub-groups, according to their duration of the diabetes (< 10, 10-14, 15-19, 20 or more years). Mean plasma glucose values at 08.00, 10.00, 20.00, 03.00 and 06.00 hours were not significantly different among the four groups. However, mean plasma glucose values at 12.00, 14.00, 18.00, 00.00 hours and mean total blood glucose area under the daily profile (total BG) were significantly different among the four groups and the values in patients with a history of diabetes of 15 years or more increased. Duration of diabetes positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00, 03.00 hours and total BG, and the dose of sulfonylureas positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00 hours and total BG in multiple regression analysis. These results suggest that duration of diabetes and dose of sulfonylureas are important determinants of blood glucose control with sulfonylureas in elderly diabetic patients. The aim of this study is to clarify the relationship between the efficacy of sulfonylureas and duration of diabetes in elderly diabetics. Daily blood glucose profiles were measured in 87 Type 2 elderly diabetic patients on sulfonylureas (tolbutamide, gliclazide or glibenclamide). Plasma glucose concentrations were determined at 08.00 (before breakfast), 10.00, 12.00 (before lunch), 14.00, 18.00 (before dinner), 20.00, 24.00, 03.00, 06.00, 08.00 hours. The subjects were divided into 4 subgroups, according to their duration of the diabetes (<10, 10-14, 15-19, 20 or more years). Mean plasma glucose values at 08.00, 10.00, 20.00, 03.00 and 06.00 hours were not significantly different among the four groups. However, mean plasma glucose values at 12.00, 14.00, 18.00, 00.00 hours and mean total blood glucose area under the daily profile (total BG) were significantly different among the four groups and the values in patients with a history of diabetes of 15 years or more increased. Duration of diabetes positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00, 03.00 hours and total BG, and the dose of sulfonylureas positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00 hours and total BG in multiple regression analysis. These results suggest that duration of diabetes and dose of sulfonylureas are important determinants of blood glucose control with sulfonylureas in elderly diabetic patients. The aim of this study is to clarify the relationship between the efficacy of sulfonylureas and duration of diabetes in elderly diabetics. Daily blood glucose profiles were measured in 87 Type 2 elderly diabetic patients on sulfonylureas (tolbutamide, gliclazide or glibenclamide). Plasma glucose concentrations were determined at 08.00 (before breakfast), 10.00, 12.00 (before lunch), 14.00, 18.00 (before dinner), 20.00, 24.00, 03.00, 06.00, 08.00 hours. The subjects were divided into 4 sub-groups, according to their duration of the diabetes (< 10, 10-14, 15-19, 20 or more years). Mean plasma glucose values at 08.00, 10.00, 20.00, 03.00 and 06.00 hours were not significantly different among the four groups. However, mean plasma glucose values at 12.00, 14.00, 18.00, 00.00 hours and mean total blood glucose area under the daily profile (total BG) were significantly different among the four groups and the values in patients with a history of diabetes of 15 years or more increased. Duration of diabetes positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00, 03.00 hours and total BG, and the dose of sulfonylureas positively correlated with blood glucose values at 12.00, 14.00, 18.00, 00.00 hours and total BG in multiple regression analysis. These results suggest that duration of diabetes and dose of sulfonylureas are important determinants of blood glucose control with sulfonylureas in elderly diabetic patients. |
| Author | Metori, Shouhei Suzuki, Tatsuya Koibuchi, Hitoshi Oba, Kenzo Yamaguchi, Yuu Okazaki, Kyoji Ajiro, Yumiko Inuzuka, Yuki Igari, Yoshimasa Nakano, Hiroshi Yano, Makoto Satoh, Shuzo Nagai, Shinya |
| Author_xml | – sequence: 1 fullname: Igari, Yoshimasa organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Okazaki, Kyoji organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Suzuki, Tatsuya organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Metori, Shouhei organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Yamaguchi, Yuu organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Koibuchi, Hitoshi organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Ajiro, Yumiko organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Satoh, Shuzo organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Inuzuka, Yuki organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Oba, Kenzo organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Nagai, Shinya organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Nakano, Hiroshi organization: The Division of Geriatric Medicine, Nippon Medical School – sequence: 1 fullname: Yano, Makoto organization: The Division of Geriatric Medicine, Nippon Medical School |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10614126$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kM1OAyEURllotNY-gBszK3etUBhmWGrrX9JEE3VNGOaiGAoVZhZ9e6lVa0zccDfnfJf7HaE9HzwgdELwhBJGz18gWtVFq9OE8klFyj00wBTjsSAVPUSjlGyDy5oJxjk-QIcEc8LIlA_Q7LF3Jvi16yOoVCjfFnNl3bq4dCG0xY3rdUhQPMRgrINUWF9cuRZiJuZWNdDlncdo3yiXYPQ1h-j5-uppdjte3N_czS4WY01rUo41VLWoFa-mmtWCt8Qw1rLatIIbYTTXQigCTIsqf01UjWnqspxizFXLcMk0HaKzbe4qhvceUieXNmlwTnkIfZJc0LyhxBk8_QL7ZgmtXEW7VHEtv8_OQLUFdAwpRTBS2051Nvgu5uszKDe9yl2vknKZe80m-WPuwv93FlvnLXXqBX4MFXN7Dn4ZRHC2sTZZn2_WfzD9qqIETz8AxIKbPg |
| CitedBy_id | crossref_primary_10_1111_j_1447_0594_2005_00282_x |
| ContentType | Journal Article |
| Copyright | The Japan Geriatrics Society |
| Copyright_xml | – notice: The Japan Geriatrics Society |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3143/geriatrics.36.715 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EndPage | 720 |
| ExternalDocumentID | 10614126 10_3143_geriatrics_36_715 article_geriatrics1964_36_10_36_10_715_article_char_en |
| Genre | Research Support, Non-U.S. Gov't English Abstract Journal Article |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS CS3 F5P JSF KQ8 OK1 RJT 123 2WC AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c3815-ce7898a672c4896d1f44d48fd96f9fc6c99a1e4c9741297bfb8552006ad4054c3 |
| ISSN | 0300-9173 |
| IngestDate | Thu Jul 10 18:12:37 EDT 2025 Wed Feb 19 02:33:46 EST 2025 Thu Apr 24 23:09:07 EDT 2025 Tue Jul 01 00:43:57 EDT 2025 Wed Sep 03 06:29:11 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 10 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c3815-ce7898a672c4896d1f44d48fd96f9fc6c99a1e4c9741297bfb8552006ad4054c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/geriatrics1964/36/10/36_10_715/_article/-char/en |
| PMID | 10614126 |
| PQID | 69378950 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_69378950 pubmed_primary_10614126 crossref_citationtrail_10_3143_geriatrics_36_715 crossref_primary_10_3143_geriatrics_36_715 jstage_primary_article_geriatrics1964_36_10_36_10_715_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 1900 |
| PublicationDate | 1999-00-00 |
| PublicationDateYYYYMMDD | 1999-01-01 |
| PublicationDate_xml | – year: 1999 text: 1999-00-00 |
| PublicationDecade | 1990 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Nihon Rōnen Igakkai zasshi |
| PublicationTitleAlternate | Nippon Ronen Igakkai Zasshi |
| PublicationYear | 1999 |
| Publisher | The Japan Geriatrics Society |
| Publisher_xml | – name: The Japan Geriatrics Society |
| References | 15) Matsuda A, Kuzuya T, Sugita Y, Kawashima K: Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res 1983; 15: 425-428. 12) Wahlin-Boll E, Sartor G, Melander A, Schersten B: Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 1982; 22: 21-25. 17) Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-935. 9) Groop L, Schalin C, Franssila-Kallunki A, Widen E, Ekstrand A, Eriksson J: Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989; 87: 183-190. 10) Sonksen PH, Lowy C, Perkins JR, West TET: Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in cross-over study in diabetics not controlled by diet alone. Diabetologia 1981; 20: 22-30. 6) 河盛隆造: 糖の流れからみたNIDDMの成因. 内科 1995; 76: 46-53. 14) Karam JH, Sanz N, Salamon E, Nolte MS: Selective unresponsiveness of pancreatic β-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 1986; 35: 1314-1320. 19) 小坂樹徳, 葛谷健, 赤沼安夫, 繁田幸男, 兼子俊男: 新しい経口血糖降下薬CS-045のインスリン非依存糖尿病患者に対するSU剤との併用投与における臨床評価-プラセボを対照薬とした二重盲検比較試験-. 臨床医薬 1993; 9 (Suppl. 3): 95-126. 11) Melander A: Oral antidiabetic drugs: an overview. Diabetic Med 1996; 13: S143-S147. 8) 久保田稔, 辻野高史, 池田雅彦, 山崎義光: インスリン分泌能とインスリン抵抗性の診断法. 臨床医 1996; 22: 563-567. 18) UK Prospective Diabetes Study Group: UKPDS28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92. 4) UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. 16) 大庭建三, 鯉渕仁, 松浦良樹, 岡崎恭次, 網代由美子, 佐藤周三ほか: スルホニル尿素薬療法中の老年者糖尿病の血糖管理-朝食前血糖値測定の臨床的意義-. 日老医誌 1999; 36: 122-127. 2) 鎌田郁子, 岩本安彦, 松田文子, 葛谷健: 糖尿病患者のインスリン依存性判定の指標としてのグルカゴン負荷時血清Cペプチド反応. 糖尿病1985; 28: 827-831. 5) Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, et al: Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabetic Med 1988; 5: 36-41. 1) Groop L: Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754. 13) Stenman S, Melander A, Groop P-H, Groop LC: What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-172. 3) U. K. Prospective Diabetes Study Group: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258. 7) 松田文子: 尿C-ペプチド. 日本臨床 1998; 56 (1998臨時増刊号): 292-296. |
| References_xml | – reference: 14) Karam JH, Sanz N, Salamon E, Nolte MS: Selective unresponsiveness of pancreatic β-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 1986; 35: 1314-1320. – reference: 15) Matsuda A, Kuzuya T, Sugita Y, Kawashima K: Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res 1983; 15: 425-428. – reference: 18) UK Prospective Diabetes Study Group: UKPDS28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92. – reference: 11) Melander A: Oral antidiabetic drugs: an overview. Diabetic Med 1996; 13: S143-S147. – reference: 9) Groop L, Schalin C, Franssila-Kallunki A, Widen E, Ekstrand A, Eriksson J: Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989; 87: 183-190. – reference: 2) 鎌田郁子, 岩本安彦, 松田文子, 葛谷健: 糖尿病患者のインスリン依存性判定の指標としてのグルカゴン負荷時血清Cペプチド反応. 糖尿病1985; 28: 827-831. – reference: 1) Groop L: Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754. – reference: 8) 久保田稔, 辻野高史, 池田雅彦, 山崎義光: インスリン分泌能とインスリン抵抗性の診断法. 臨床医 1996; 22: 563-567. – reference: 3) U. K. Prospective Diabetes Study Group: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258. – reference: 6) 河盛隆造: 糖の流れからみたNIDDMの成因. 内科 1995; 76: 46-53. – reference: 17) Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-935. – reference: 10) Sonksen PH, Lowy C, Perkins JR, West TET: Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in cross-over study in diabetics not controlled by diet alone. Diabetologia 1981; 20: 22-30. – reference: 4) UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. – reference: 16) 大庭建三, 鯉渕仁, 松浦良樹, 岡崎恭次, 網代由美子, 佐藤周三ほか: スルホニル尿素薬療法中の老年者糖尿病の血糖管理-朝食前血糖値測定の臨床的意義-. 日老医誌 1999; 36: 122-127. – reference: 12) Wahlin-Boll E, Sartor G, Melander A, Schersten B: Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 1982; 22: 21-25. – reference: 13) Stenman S, Melander A, Groop P-H, Groop LC: What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-172. – reference: 7) 松田文子: 尿C-ペプチド. 日本臨床 1998; 56 (1998臨時増刊号): 292-296. – reference: 19) 小坂樹徳, 葛谷健, 赤沼安夫, 繁田幸男, 兼子俊男: 新しい経口血糖降下薬CS-045のインスリン非依存糖尿病患者に対するSU剤との併用投与における臨床評価-プラセボを対照薬とした二重盲検比較試験-. 臨床医薬 1993; 9 (Suppl. 3): 95-126. – reference: 5) Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, et al: Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabetic Med 1988; 5: 36-41. |
| SSID | ssib058494660 ssj0055462 ssib002821993 ssib005879752 ssib000994798 ssib000940319 |
| Score | 1.4398177 |
| Snippet | The aim of this study is to clarify the relationship between the efficacy of sulfonylureas and duration of diabetes in elderly diabetics. Daily blood glucose... |
| SourceID | proquest pubmed crossref jstage |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 715 |
| SubjectTerms | Aged Aged, 80 and over Blood Glucose - metabolism Circadian Rhythm Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Dialy blood glucose profile Duration of diabetes Elderly Female Humans Hypoglycemic Agents - therapeutic use Male Sulfonylurea Compounds - therapeutic use Sulfonylureas |
| Title | Sulfonylureas and Daily Blood Glucose Profiles in Elderly Diabetics |
| URI | https://www.jstage.jst.go.jp/article/geriatrics1964/36/10/36_10_715/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/10614126 https://www.proquest.com/docview/69378950 |
| Volume | 36 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 1999/10/25, Vol.36(10), pp.715-720 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgIMQL4puOLz-wF6p0aeLY8SOqhgZoQ8AmjafIcZwu60inrX3pX8-d7aRJYQh4idrkaiV318vvzvdByBsly0RoBm5qwk3AtDCBLFIdRMIksYiFUiUWJx8c8v1j9vEkOVlP6bPVJYt8pFe_rSv5H6nCOZArVsn-g2TbReEEfAb5whEkDMe_kvG35Xm5zizHEHihMFxhs9GHTTa6H8ttE18NDuUGChdybTLdPTg9rE5BF77OdyaTnZTVph5-mKrZTFXDFUDs06oNyOaqFyD9NK9ynKnSq3X4PFMrNevPuoblXGH793WwARsUdKxRHIZgGd3ckcZ0ut4ljYqEHUMoXJHmpoGOAZ4BV6coA5xAcDWK-WiDFnh88cNKzLqr42ijVbb3Xdylm-RWJGAB3I7_0gGWkmF5Vue7ZKLjWIKjiZmLa0uUCimSFugBKsO--2HzTsdUPr8f5Zjg9sfxaXZ_eRbsQ-vvrgd2bp8B3p-a610ZC2mO7pN73heh75xiPSA3ztRDcufAZ1s8IpOeflHQL2r1i1r9ol6_aKNftKqp1y_a6tdjcvx-72iyH_ihG4EG8JYE2ohUpoqLSLNU8mJcMlawtCwkL2WpuZZSjQ3T4IcCVBR5macJtu7iqgDsz3T8hGzV89o8IzQx2J_SFAX4DLAWk5HKAX3rEF7OWsdmQMKGO5n2HelxMMp5Bp4p8jZb8zaLeQa8HZC37U8uXDuWPxHvOZa3pP6f2iHFfnRIjovYI_yuJcPCR7AzA_K6kVgGxhd31FRt5surjAO4T2USDshTJ8jOTTkN2L72ynNy17UAwXDeC7K1uFyalwBwF_krq8s_AQMgncI |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sulfonylureas+and+daily+blood+glucose+profiles+in+elderly+diabetics&rft.jtitle=Nihon+Ro%CC%84nen+Igakkai+zasshi&rft.au=Oba%2C+K&rft.au=Koibuchi%2C+H&rft.au=Okazaki%2C+K&rft.au=Igari%2C+Y&rft.date=1999&rft.issn=0300-9173&rft.volume=36&rft.issue=10&rft.spage=715&rft_id=info:doi/10.3143%2Fgeriatrics.36.715&rft_id=info%3Apmid%2F10614126&rft.externalDocID=10614126 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-9173&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-9173&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-9173&client=summon |